BioSyent licensed a new patented combination of acetaminophen and ibuprofen in a single tablet for the temporary relief of mild to moderate pain. It is the first product in Canada that combines the benefit of these two analgesics into a single tablet.
Combogesic comprises two well-known analgesics: acetaminophen and ibuprofen, which are commonly prescribed together due to their synergistic effect on pain management.
Patients seeking relief from pain value effectiveness above all else. Only for a very compelling reason will they walk away from their tried and true preferred forms of pain therapy.
Our design strategy focused on telling the visual story of two is better than one. By leveraging familiar visual cues from the pain management category, we positioned Combogesic as a better version of the analgesics with which they are already familiar. The colours selected subconsciously connected to prominent acetaminophen and ibuprofen brands (red and blue respectively) and the visual overlap of the colours symbolizes the two medicines coming together. To further communicate this product’s dual offering, a ‘double action’ icon was developed as well as a visually contrasting flash at the top of the pack clearly stating the two analgesics.
An iconic wordmark was developed for the Combogesic brand that used a bold font combination to highlight the word ‘Combo’, subtly reinforcing the “two is better than one” design intent. The strong brand treatment instills confidence in the effectiveness, which is particularly important in a category where consumers don’t want to compromise on performance.